Nectar Lifesciences gets approval; to raise $50 million
Pharmaceutical major Nectar Lifesciences informed that it will raise 50 million dollar through the issue of securities in international markets. Today, the company’s board of directors at its meeting has finally approved to issue Global Depository Receipts (GDRs), American Depository Receipts (ADRs) or any other international offering of up to 50 million US dollars.
Apart from this, the board of directors has also approved the signing of non binding term sheets for issue of preferential equity with Citi Venture Capital International and Everest Capital (M) Ltd.
Nectar Lifesciences Limited engages in the manufacture and sale of semi synthetic penicillin and cephalosporin-based oral and sterile bulk drugs in India.
The company further stated that it would seek shareholders approval in an extra ordinary general meeting proposed to be convened on September 16.






